ArticleJACC. Case reports2025
Molecular Characterization of Pericardial Mesothelioma With Constrictive and Recurrent Pericarditis: TAZ Amplification and Hippo Pathway.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pericardial mesothelioma (MPM) is a rare, aggressive neoplasm with nonspecific clinical presentations. Although BAP1 loss and CDKN2A deletion are common in pleural mesothelioma, they are not universally present in MPM, complicating diagnosis. CASE SUMMARY: A 73-year-old man presented with recurrent fever and chest pain from pericarditis. Positron emission tomography-computed tomography and transthoracic echocardiography revealed pericardial thickening and aortitis, concerning for inflammatory or infectious etiology. Initial histopathology was inconclusive. Diagnosis of MPM was confirmed via lymph node biopsy and molecular profiling, which revealed TAZ amplification. The patient was treated with IL-1 blockage and chemotherapy, with symptom improvement. DISCUSSION: In BAP1/CDKN2A-negative mesothelial proliferations, molecular testing for additional mutations, including TAZ amplification, may guide diagnostic certainty and novel therapeutic treatment. TAKE-HOME MESSAGES: MPM can closely mimic chronic inflammatory disease, and accurate diagnosis with comprehensive profiling is essential to guide targeted therapy. TAZ amplification suggests Hippo pathway as a driver of BAP-intact tumors and may serve as a predictive biomarker of mesothelial immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.